Annals of African medicine · 2026
Estimation of Urinary Marinobufagenin in Stable Chronic Kidney Disease Patients: A Hospital-based Cross-sectional Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Verma Nivedita, Sachan Achintya, Patel Munna Lal, Sachan Rekha, Ali Wahid
Аннотация
BACKGROUND: Chronic kidney disease (CKD) is associated with accumulation of endogenous cardiotonic steroids, including marinobufagenin (MBG), a bufadienolide that inhibits Na+/K+-ATPase and promotes renal and cardiac fibrosis. Urinary MBG (uMBG) excretion reflects glomerular filtration and may decline as renal function deteriorates, yet data from Indian populations are lacking.
OBJECTIVES: To estimate uMBG levels in stable CKD patients (kidney disease improving global outcomes stages 2-4), to correlate these levels with markers of renal function and CKD severity, and to assess the diagnostic utility of uMBG as a biomarker.
METHODS: A hospital-based cross-sectional study was conducted in department of medicine King George's Medical University, Lucknow over a period of 1 year. Seventy stable CKD patients (stages 2-4) and 25 age-and sex-matched healthy controls were enrolled. uMBG was estimated by competitive enzyme-linked immunosorbent assay method.
RESULTS: uMBG was significantly lower in CKD patients compared to controls (median 6.85 [interquartile range 4.95-8.59] vs. 11.78 [10.61-12.3] pg/mL; P < 0.001). A highly significant inverse gradient was observed across CKD stages 2-4 (Kruskal-Wallis H = 60.698; P < 0.001; Kendall's τ = -0.826; P < 0.001). Estimated glomerular filtration rate was the dominant correlate of uMBG (ρ = 0.976; P < 0.001) and the sole independent predictor on multivariate regression (β = 0.00708; P < 0.001; R2 = 0.672). Receiver operating characteristic analysis yielded an area under the curve (AUC) of 0.914 with sensitivity 82.6% and specificity 100% at a cut-off of 9.3 pg/mL.
CONCLUSION: uMBG is significantly reduced in stable CKD and declines progressively with advancing disease stage, mirroring the decline in glomerular filtration rate. uMBG has the ability to be a novel, stage-sensitive biomarker for CKD due to its excellent diagnostic accuracy (AUC 0.914).
OBJECTIVES: To estimate uMBG levels in stable CKD patients (kidney disease improving global outcomes stages 2-4), to correlate these levels with markers of renal function and CKD severity, and to assess the diagnostic utility of uMBG as a biomarker.
METHODS: A hospital-based cross-sectional study was conducted in department of medicine King George's Medical University, Lucknow over a period of 1 year. Seventy stable CKD patients (stages 2-4) and 25 age-and sex-matched healthy controls were enrolled. uMBG was estimated by competitive enzyme-linked immunosorbent assay method.
RESULTS: uMBG was significantly lower in CKD patients compared to controls (median 6.85 [interquartile range 4.95-8.59] vs. 11.78 [10.61-12.3] pg/mL; P < 0.001). A highly significant inverse gradient was observed across CKD stages 2-4 (Kruskal-Wallis H = 60.698; P < 0.001; Kendall's τ = -0.826; P < 0.001). Estimated glomerular filtration rate was the dominant correlate of uMBG (ρ = 0.976; P < 0.001) and the sole independent predictor on multivariate regression (β = 0.00708; P < 0.001; R2 = 0.672). Receiver operating characteristic analysis yielded an area under the curve (AUC) of 0.914 with sensitivity 82.6% and specificity 100% at a cut-off of 9.3 pg/mL.
CONCLUSION: uMBG is significantly reduced in stable CKD and declines progressively with advancing disease stage, mirroring the decline in glomerular filtration rate. uMBG has the ability to be a novel, stage-sensitive biomarker for CKD due to its excellent diagnostic accuracy (AUC 0.914).